Form 8K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 17, 2008

 

REGENERATION TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   0-31271   59-3466543

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

11621 Research Circle, Alachua, Florida   32615
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (386) 418-8888

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01 Other Events.

On January 17, 2008, Regeneration Technologies, Inc. (“RTI”) and Tutogen Medical, Inc. (“Tutogen”) issued a press release announcing that with the proposed merger of the two companies, RTI will ask its shareholders to approve a new company name, RTI Biologics, Inc., at the special meeting of the stockholders of RTI scheduled for February 27, 2008. The stock will continue to trade on the Nasdaq Global Market under the symbol RTIX.

A copy of the press release is furnished herewith as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

  99.1 Press Release dated January 17, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REGENERATION TECHNOLOGIES, INC.
Date: January 17, 2008   By:  

/s/ Thomas F. Rose

  Name:   Thomas F. Rose
  Title:   Vice President and Chief Financial Officer

EXHIBIT INDEX

 

99.1 Regeneration Technologies, Inc. press release dated January 17, 2008.